Such myofibroblast-deleted tumours enhanced tumour hypoxia, EMT program and CD44+CD133+ CSC phenotype, while decreased angiogenesis and cytotoxic CD8+/Treg ratio [72]. This evidence concerns the gene CD44 and neoplasm.